Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...

33rd Psychiatric Pharmacotherapy Update 2021 - Live and Virtual


2021 Virtual Event


The University of Texas College of Pharmacy welcomes you to the 33rd Psychiatric Pharmacotherapy Update.  This CE activity offers 20 hours of psychiatric focused continuing education. 


 

VIRTUAL LIVE BROADCAST

We  offer a Live Broadcast where registrants will view the entire program online on October 21 and 22.  The live broadcast will bring to your computer the live in-person sessions through this registration system.  No additional applications or sign ups necessary.  Experience the Psychiatric Pharmacotherapy Update from the comfort of your office or home.  If your schedule does not allow for you to view all content live, no worries!  Recordings of all live programming will be available On-Demand shortly after the live broadcast for you to view and complete CE over the next year!

[NOTE: Originally the Update was hosting a limited in-person option.  Due to COVID-19 surges locally, the in-person option has been canceled.  The Update is virtual only this year, see more information here.]

 

Additional On-Demand Content

The Psychiatric Pharmacotherapy Update also offers additional On-Demand content that is available to all registrants.  On-Demand content includes an additional 8 video-based CE programs that may be viewed at anytime over the next year.  This allows registrants to pick and choose the options that fit best with their personal practice. 

 

 
 

Registration / Access Content Information:

  1. Scroll down and click on the "register now" button.  Set up a new ID or log in to your existing account.  Use the "forgot password" feature to retrieve your log on information.
  2. Bookmark this page!  This is the same log on site that will be used during the event for viewing presentation slides, viewing the live broadcasts, access on-demand sessions and access to complete evaluations for CE credit.
  3. Anytime, return to this page, log in, (if it does not return you automatically to this page, just click the "Assess Content" in the banner on the home page). Then scroll down below, and you will see the webinar links and content inside the tabs below.
For more information, please see the conference full website here.
 

Date: Oct 21, 2021 08:30 AM - Oct 22, 2021 04:30 PM

Fee

$375.00

CE Hours

20.00

CE Units

2.000

Registration closes on Oct 22, 2021 01:00 AM

Activity Type

  • Knowledge

 

 

 

   

 
Live Welcome and Opening Announcements
 
  • The conference opening will be broadcast via Zoom.  The broadcast zoom link will appear on the day of the event.
 
 
Date: 10/21/21
Time: 08:15 AM - 08:30 AM
   

   

 
Psychotropic New Drug Update
 
 
Stephen R. Saklad, Phrm.D., BCPP
Clinical Professor of Pharmacotherapy
Director, Psychiatric Pharmacy Program
Adjoint Professor, School of Medicine
Clinical Pharmacologist, San Antonio State Hospital, Texas Department of State Health Services
 
 
LEARNING OBJECTIVES
  • Describe the pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs recently marketed as well as drugs approaching the market.
  • Review pharmacology, adverse effects, drug interactions, therapeutic uses, and dosing of selected psychiatric drugs that have been released in the past five years.
ABOUT THE FACULTY

Dr. Saklad was born in Los Angeles, California in 1953, and graduated from Pacific Palisades High School in 1970. He received his baccalaureate degree cum laude in Bacteriology from the University of California, Los Angeles in 1974. His Doctor of Pharmacy degree was earned at the University of Southern California in 1978. He had a National Institute of Mental Health training fellowship in Psychiatric Pharmacy supervised by Jim Wilson, Pharm.D., BCPP at the Nebraska Psychiatric Institute of the University of Nebraska Medical Center at Omaha in 1978-9. He then joined the faculty of The University of Texas at Austin College of Pharmacy and the clinical staff at San Antonio State Hospital (SASH) in 1979. He was the first clinical pharmacist employed by the Texas Department of Mental Health and Mental Retardation (now Texas Health and Human Services) when he began as Clinical Coordinator at SASH. He has lived in San Antonio, Texas since 1979. He is married and the father of triplet sons.

During his 38 years career, Dr. Saklad has provided clinical care, education, and research in a variety of settings and treatment roles at SASH. He team teaches didactic courses for second and third professional year pharmacy students. He is the course director for Advanced Pharmacotherapy Laboratory, a third professional year opportunity for students to develop their clinical presentation skills that is given across four campuses. He precepts and mentors third and fourth professional year pharmacy students (P3’s & P4’s) at SASH. He received the UT Austin College of Pharmacy’s Teaching Award from the Class of 2014. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at SASH that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH.

Dr. Saklad initiated and developed the first websites for the UT Austin College of Pharmacy in 1994, the College of Psychiatric and Neurologic Pharmacists (CPNP) in 1997, and the CPNP Foundation in 2015. He helped to design, organize and was a founding member of CPNP when it incorporated in 1998 as well as the CPNP Foundation in 2012. In 2003, he was elected to the Board of Directors of the CPNP for a two-year term. He has served as a member or officer of the CPNP Communications Committee since the creation of CPNP from 1995 to 2011 and was the Founding Senior Editor of the Mental Health Clinician, CPNP’s Open Access journal, from 2011-13. Currently, Dr. Saklad is Treasurer of the CPNP Foundation a member of the CPNP Business Development Committee. He was on the task force that developed The Mental Health Pharmacy Directory to improve patient access. He is the Director of The University of Texas Psychiatric Pharmacy Program. In 1988, he helped to create and has chaired The University of Texas at Austin College of Pharmacy’s Psychiatric Pharmacotherapy Update since 2007.

Dr. Saklad publishes articles and presents to many groups around the country on a variety of pharmacy and mental health-related topics. He edited Psychopharmacology Update newsletter from 1998-2002 and edited two editions of a compendium based upon this newsletter, Psychopharmacology Desktop Reference, published by Manisses Communications Group in 1999 and 2002. He provides updates on his Twitter feed on a variety of topics @pharmacopsych.

Dr. Saklad is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, depression, and other serious and persistent mental illness, as well as their pharmacokinetics and interactions. He was the Director of UT Health Science Center San Antonio’s Advanced Pharmacotherapy Research with research facilities located at Laurel Ridge Treatment Center and President of Alamo Superior Research, LLC. He has been affiliated with the Behavioral Wellness (“Be Well”) Center, Department of Psychiatry, UT Health San Antonio since 2009.


Disclosure: Dr. Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Employee of Texas Department of Health Services San Antonio
Speakers Bureau: Actavis, Otsuka, Sunovion
Consultant: Janssen, Jazz, Otsuka, Teva
Other: Member of Pharmacists Foundation, Business Development Council for San Antonio

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

 
 
Date: 10/21/21
Time: 08:30 AM - 09:30 AM

CE Hours

1.00
   

   

 
Reducing Suicide Among Youth, Their Families and Communities with the Columbia Protocol
 
 
Kelly Posner Gerstenhaber, PhD
Professor, Columbia University
Founder and Director, The Columbia Lighthouse Project
Recipient, Secretary of Defense Medal for Exceptional Public Service
Columbia University/New York State Psychiatric Institute
 
 
 
LEARNING OBJECTIVES
  • Discuss how preventative suicide screening models can be used to identify at-risk individuals and establish care plans that reduce suicide while allocating resources effectively.
  • Utilize a systemic best-practice measurement, the C-SSRS, to identify suicidal ideation and behavior to improve risk identification and safety monitoring, which ultimately aids prevention.
  • Demonstrate how the C-SSRS enables more streamlined triage, provides liability protection and facilitates care delivery to those at highest risk.
  • Identify steps taken to implement a comprehensive screening program within an agency.
ABOUT THE FACULTY
  • TBA
 
 
Date: 10/21/21
Time: 09:45 AM - 10:45 AM

CE Hours

1.00
   

   

 
Update on Childhood Aggression
 
 
Joseph Blader, PhD
Meadows Foundation & Semp Russ Professor of Child Psychiatry 
Departments of Psychiatry & Behavioral Sciences and Pediatrics 
Joe R. and Teresa Lozano Long School of Medicine
University of Texas Health Science Center at San Antonio
 
LEARNING OBJECTIVES
  • Discuss current non-pharmacological and pharmacological strategies for treatment of aggression among children with psychiatric disorders
  • Discuss growing evidence to support the treatment of aggression associated with externalizing disorders in children and adolescents.
  • Adverse effect liabilities of pharmacotherapies often used for aggressive behavior • Discuss step approach to treatments, and societal concerns about medications for behavioral disorders in youth.
 
 
Date: 10/21/21
Time: 11:00 AM - 12:00 PM

CE Hours

1.00
   

   

 
Lunch Break
 
 
Enjoy a break! 
 
 
 
Date: 10/21/21
Time: 12:00 PM - 01:00 PM
   

   

 
Treatment of Psychiatric Symptoms in Neurocognitive Disorders
 
 
Jason Schillerstrom, M.D.
Professor, Department of Psychiatry
The University of Texas Health Science Center San Antonio  
 
 
LEARNING OBJECTIVES
  • Review new and emerging therapies as well as risks associated with current pharmacotherapies
  • Evaluate evidence and risk vs. benefit of medication treatment as well as any nonmedication modalities
  • Review current blackbox warnings and potential ethical issues related to patient communication
 
 
Date: 10/21/21
Time: 01:00 PM - 02:00 PM

CE Hours

1.00
   

   

 
Appropriate Use of Complementary and Alternative Medicines (CAM) for Psychiatric Disorders
 
 
Marisa S. P. Toups, M.D.
Psychiatrist
Singularity Psychiatry and Mental Health
 
 
LEARNING OBJECTIVES
  • TBA
 
 
Date: 10/21/21
Time: 02:15 PM - 03:15 PM

CE Hours

1.00
   

   

 
Managing Dual Diagnosis: Substance Use and Psychiatric Disorders
 
 
Amanda Simonton, PhD, APRN, PMHNP-BC
Clinical Assistant Professor
The University of Texas at Austin School of Nursing
 
 
LEARNING OBJECTIVES
  • TBA
ABOUT THE FACULTY

Amanda J. Simonton, PhD, APRN, PMHNP-BC is a Clinical Assistant Professor at the University of Texas at Austin School of Nursing and Psychiatric Mental Health Nurse Practitioner at the Texas Child Study Center at Dell Children’s Medical Center. She has been a Registered Nurse since 2013 and previously worked in the Intermediate Care Unit at Seton Medical Center Austin and Psychiatric Emergency Department at University Medical Center Brackenridge. As a psychiatric nurse practitioner, she has primarily worked with adults with dual-diagnosed (substance use and mental health) disorders and with children and adolescents. She earned her Bachelor of Science in Nursing (’13), Master of Science in Nursing (’18), and Doctor of Philosophy (’20) through the School of Nursing at the University of Texas at Austin. She is active in presenting at the annual conferences for Texas Nurse Practitioners and the American Psychiatric Nurses Association. She is currently on the Policy Council for Texas Nurse Practitioners and the President-Elect on the American Psychiatric Nurses Association Texas Chapter Board of Directors. Dr. Simonton is also a member of two steering committees, which focus on treatment of schizophrenia spectrum disorders and bipolar depression, for Medscape Inc. Her research and clinical interests are to improve the lives of individuals with substance use disorders and serious mental illness by utilizing evidence-based care and best-practices in the field of psychiatry and psychology.


Disclosure: Dr. Simonton has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.

 
 
Date: 10/21/21
Time: 03:30 PM - 04:30 PM

CE Hours

1.00
   

   

 
Day I Programming Concludes
 
 
Thank you for joinging us on Day 1
  • You can complete the online evaluations for day 1
 
 
Date: 10/21/21
Time: 04:30 PM - 04:30 PM
   

   

 
VIRTUAL Reception
 
 
Join us for a reception following the end of Day 1 sessions.
  • Details TBA
 
 
Date: 10/21/21
Time: 05:00 PM - 06:30 PM
   

 

   

 
Live Welcome and Opening Announcements
 
  • The conference opening will be broadcast live as part of the first session.
 
 
Date: 10/22/21
Time: 08:25 AM - 08:30 AM
   

   

 
Medication Treatment of Co-Occurring Opioid and Alcohol Use Disorders
 
 
Faculty - Lucas Hill, Pharm.D., BCPS, BCACP
Clinical Associate Professor
The University of Texas at Austin College of Pharmacy
 
 
LEARNING OBJECTIVES
  • Describe recent trends in use and harms of opioids and alcohol
  • Summarize current evidence and key ethical issues related to medication treatment of co-occurring opioid and alcohol use disorders
  • Develop a medication treatment plan for a patient with co-occurring opioid and alcohol use disorders that integrates patient-specific factors relevant to psychiatric clinicians
ABOUT THE FACULTY
 
Lucas G. Hill, PharmD, BCPS, BCACP, graduated from the University of Missouri-Kansas City School of Pharmacy and completed a combined family medicine residency and faculty development fellowship in the University of Pittsburgh Medical Center St. Margaret Department of Family Medicine. He is now a clinical assistant professor at The University of Texas at Austin (UT) College of Pharmacy. Dr. Hill is the director and principal investigator of Operation Naloxone, an interprofessional opioid overdose prevention program funded through the Texas Targeted Opioid Response. His research is focused on clinician-community collaborations to address substance use disorders through evidence-based treatment and harm reduction strategies. Dr. Hill coordinates the first year of the UT Foundations for Interprofessional Collaborative Practice curriculum and serves as lead instructor for a module that trains students from pharmacy, medicine, nursing, and social work to provide team-based care for patients with addiction. He provides an additional 16 hours of addiction-related instruction in the required pharmacy curriculum and precepts both the overdose prevention introductory pharmacy practice experience and the addiction medicine advanced pharmacy practice experience. Dr. Hill currently serves as chair-elect of the American Association of Colleges of Pharmacy Substance Use Disorder Special Interest Group. He is also faculty advisor for the UT Student Pharmacist Recovery Network and co-chair for the UT Opioid Response Consortium. In 2020, Dr. Hill was awarded the American Pharmacists Association Generation Rx Award of Excellence in recognition of his outstanding contributions to addiction-related education.

Disclosure: Dr. Hill receives financial support from the Substance Abuse and Mental Health Services Administration and the Texas Health and Human Services Commission via the Texas Targeted Opioid Response.
Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.
 
 
 
Date: 10/22/21
Time: 08:30 AM - 09:30 AM

CE Hours

1.00
   

   

 
Schizophrenia Update
 
 
Troy A. Moore, Pharm.D., M.S, BCPP
Director ASHP Accredited PGY-1 Pharmacy Residency Program
Clinical Pharmacy Specialist, Mental Health
Rocky Mountain Regional VA Medical Center
 
 
LEARNING OBJECTIVES
  • Assess the impact of co-occurring disorders on schizophrenia
  • Discriminate between the new potential drug targets in schizophrenia and how they may impact the treatment of schizophrenia
  • Evaluate some of the new literature examining medication treatment in schizophrenia and how it will impact outcomes
ABOUT THE FACULTY

Troy A. Moore received his PharmD from the University of New Mexico College of Pharmacy in 2003. He subsequently attended the University of Texas at Austin College, receiving his Master of Science in Pharmacy in 2005 while completing a 2 year Psychiatric Pharmacy at the San Antonio State Hospital and the South Texas Veterans Health Care System (STVHCS). He joined the University of Texas Health Science Center at San Antonio Department of Psychiatry, Division of Schizophrenia and Related Disorders in 2005 and became Assistant Professor in 2007. He joined the STVHCS as Clinical Pharmacy Specialist in Psychiatry in 2010 where he served the Substance Abuse and Domiciliary Programs. He accepted an appointment as the PGY-1 Pharmacy Residency Program Director and Clinical Pharmacy Specialist in Mental Health at the VA Eastern Colorado Health Care System (ECHCS) in Aurora, CO in December 2018. He currently a member of the ECHCS PTSD Clinical Team (PCT) program. He has also been on the planning committee for UT Psych Update since 2007


Disclosure: Dr. Moore has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.

 
 
Date: 10/22/21
Time: 09:45 AM - 10:45 AM

CE Hours

1.00
   

   

Treating Behavioral Manifestations of Traumatic Brain Injury
 
Muhammad Baig, M.D.
Research Instructor of Psychiatry and Physician
Department of Psychiatry UT Health Science Center San Antonio
 
 
LEARNING OBJECTIVES
  • Describe the classification of Traumatic Brain Injury (TBI).
  • Describe behavioral manifestations of TBI.
  • Discuss the management of individuals with TBI
 
 
Date: 10/22/21
Time: 11:00 AM - 12:00 PM

CE Hours

1.00
   

   

 
Lunch Break
 
 
Enjoy a break! 
 
 
 
Date: 10/22/21
Time: 12:00 PM - 01:00 PM
   

   

 
Use of Psychotropic Serum Concentrations in Clinical Practice
 
 
Stephen R. Saklad, Phrm.D., BCPP
Clinical Professor of Pharmacotherapy
Director, Psychiatric Pharmacy Program
Adjoint Professor, School of Medicine
Clinical Pharmacologist, San Antonio State Hospital, Texas Department of State Health Services
 
 
LEARNING OBJECTIVES
  • Review of which medications can have meaningful levels drawn
  • Discuss how to use meaningful levels in clinical practice
  • Discuss subtherapeutic levels / toxic levels
  • Include genetics topic / ethics topic and testing of genetics testing
ABOUT THE FACULTY

Dr. Saklad was born in Los Angeles, California in 1953, and graduated from Pacific Palisades High School in 1970. He received his baccalaureate degree cum laude in Bacteriology from the University of California, Los Angeles in 1974. His Doctor of Pharmacy degree was earned at the University of Southern California in 1978. He had a National Institute of Mental Health training fellowship in Psychiatric Pharmacy supervised by Jim Wilson, Pharm.D., BCPP at the Nebraska Psychiatric Institute of the University of Nebraska Medical Center at Omaha in 1978-9. He then joined the faculty of The University of Texas at Austin College of Pharmacy and the clinical staff at San Antonio State Hospital (SASH) in 1979. He was the first clinical pharmacist employed by the Texas Department of Mental Health and Mental Retardation (now Texas Health and Human Services) when he began as Clinical Coordinator at SASH. He has lived in San Antonio, Texas since 1979. He is married and the father of triplet sons.

During his 38 years career, Dr. Saklad has provided clinical care, education, and research in a variety of settings and treatment roles at SASH. He team teaches didactic courses for second and third professional year pharmacy students. He is the course director for Advanced Pharmacotherapy Laboratory, a third professional year opportunity for students to develop their clinical presentation skills that is given across four campuses. He precepts and mentors third and fourth professional year pharmacy students (P3’s & P4’s) at SASH. He received the UT Austin College of Pharmacy’s Teaching Award from the Class of 2014. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at SASH that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH.

Dr. Saklad initiated and developed the first websites for the UT Austin College of Pharmacy in 1994, the College of Psychiatric and Neurologic Pharmacists (CPNP) in 1997, and the CPNP Foundation in 2015. He helped to design, organize and was a founding member of CPNP when it incorporated in 1998 as well as the CPNP Foundation in 2012. In 2003, he was elected to the Board of Directors of the CPNP for a two-year term. He has served as a member or officer of the CPNP Communications Committee since the creation of CPNP from 1995 to 2011 and was the Founding Senior Editor of the Mental Health Clinician, CPNP’s Open Access journal, from 2011-13. Currently, Dr. Saklad is Treasurer of the CPNP Foundation a member of the CPNP Business Development Committee. He was on the task force that developed The Mental Health Pharmacy Directory to improve patient access. He is the Director of The University of Texas Psychiatric Pharmacy Program. In 1988, he helped to create and has chaired The University of Texas at Austin College of Pharmacy’s Psychiatric Pharmacotherapy Update since 2007.

Dr. Saklad publishes articles and presents to many groups around the country on a variety of pharmacy and mental health-related topics. He edited Psychopharmacology Update newsletter from 1998-2002 and edited two editions of a compendium based upon this newsletter, Psychopharmacology Desktop Reference, published by Manisses Communications Group in 1999 and 2002. He provides updates on his Twitter feed on a variety of topics @pharmacopsych.

Dr. Saklad is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, depression, and other serious and persistent mental illness, as well as their pharmacokinetics and interactions. He was the Director of UT Health Science Center San Antonio’s Advanced Pharmacotherapy Research with research facilities located at Laurel Ridge Treatment Center and President of Alamo Superior Research, LLC. He has been affiliated with the Behavioral Wellness (“Be Well”) Center, Department of Psychiatry, UT Health San Antonio since 2009.


Disclosure: Dr. Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Employee of Texas Department of Health Services San Antonio
Speakers Bureau: Actavis, Otsuka, Sunovion
Consultant: Janssen, Jazz, Otsuka, Teva
Other: Member of Pharmacists Foundation, Business Development Council for San Antonio

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

 
 
Date: 10/22/21
Time: 01:00 PM - 02:00 PM

CE Hours

1.00
   

   

 
Eating Disorder Update
 
 
Sean Kerrigan, M.D.
Psychiatrist
UT Health Austin Pediatric Psychiatry at Dell Children’s
 
Hani Talebi, Ph.D.,
LSSP Director, Pediatric Psychology Texas Child Study Center, Dell Children's Medical Center
Assistant Professor, Dept of Psychiatry and Behavioral Sciences The University of Texas at Austin Dell School of Medicine
 
 
LEARNING OBJECTIVES
  • Discuss evidence-based treatments for eating disorders
  • Discuss Vyvanse use for binge eating disorder
  • Discuss role of psychotherapy and other approaches in the treatment of eating disorders
ABOUT THE FACULTY
 
Hani Talebi, PhD, LSSP, is a licensed pediatric psychologist and the Director of Pediatric Psychology for UT Health Austin Pediatric Psychiatry at Dell Children’s. With more than 20 years of experience, he specializes in consultation/liaison psychology, parent management training, and brief evidence-based interventions for medically fragile children. Additionally, Dr. Talebi is an assistant professor in the Dell Medical School Department of Psychiatry and Behavioral Sciences. Dr. Talebi earned his combined doctorate in clinical, counseling, and school psychology with a specialization in clinical child and adolescent psychology from the University of California, Santa Barbara and his bachelor’s in cognitive science with a focus on infant cognition and evidence-based treatment of externalizing behavior disorders from the University of California, Irvine. He completed an internship in pediatric psychology at the Children’s Hospital of Orange County and a fellowship pediatric trauma at Child Abuse Listening and Mediation at the University of California, Santa Barbara. He also completed a clinical research assistantship at Children’s National Medical Center, where he oversaw clinical trials investigating the efficacy of various interventions for attention-deficit/hyperactivity disorder and other comorbid conditions. Dr. Talebi currently serves as the psychology service chief for the Consultation/Liaison Mental Health team at Dell Children’s Medical Center. He has accrued technical aptitude in numerous evidence-based modalities, including individual and group cognitive behavioral therapy, behavioral classroom management and parent training, and motivational interviewing. His research interests focus on decreasing all hospital readmission rates for children diagnosed with chronic illness.
 
Disclosure: Dr. Talebi has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose.
 
 
 
Date: 10/22/21
Time: 02:15 PM - 03:15 PM

CE Hours

1.00
   

   

 
Evaluating the Evidence for Teratogenicity of Psychotropic Medications
 
 
Jeffrey Newport, M.D.
Director of Women’s Reproductive Mental Health
UT Health Austin
 
 
LEARNING OBJECTIVES
  • Review evidence-based data regarding potential teratogenicity of psychotropic medications
  • Discuss best practices regarding use of psychotropic medications during and after pregnancy
 
 
Date: 10/22/21
Time: 03:30 PM - 04:30 PM

CE Hours

1.00
   

   

 
Closing Remarks - Thank you
 
  • Thank you for attending the 2021 Psychiatric Pharmacotherapy Update
 
 
Date: 10/22/21
Time: 04:30 PM - 04:30 PM
   

   

 
Overall Evaluation
 
  • Please complete the overall evaluation providing feedback on the full event.  Your feedback is critical for our future program planning.
  • Thank you for attending and taking time to submit your feedback.
 
 
Date: 10/22/21
Time: 04:30 PM - 04:30 PM
   

   

 
On-Demand Sessions
 
  • The following tabs below include the On-Demand optional sessions
  • Click on the tabs for the content you wish to view
  • View the video and complete the post-test, then the evaluations
  • The on-demand sessions will be availalbe for 1 year. You may return at anytime to complete.
 
 

   

   

 
The Management of Behavioral and Psychological Symptoms of Dementia (BPSD) in the Era of Boxed Warnings
 
 
Rajesh R. Tampi, M.D., M.S., D.F.A.P.A
Professor of Psychiatry
Case Western Reserve University School of Medicine
Associate Clinical Professor of Psychiatry, Yale School of Medicine
President Elect, American Association for Geriatric Psychiatry
 
LEARNING OBJECTIVES
  • TBA
ABOUT THE FACULTY

Dr. Tampi is the Chairman, Department of Psychiatry & Behavioral Sciences, Cleveland Clinic Akron General, Akron, Ohio and the Chief, Section for Geriatric Psychiatry, Cleveland Clinic in Cleveland, Ohio. In addition, he is a Professor of Medicine, Cleveland Clinic Learner College of Medicine of Case Western Reserve University and a Professor of Psychiatry at North East Ohio Medical University. Dr. Tampi also maintains his appointment as an Adjunct Professor of Psychiatry at Yale School of Medicine, New Haven, Connecticut.  Dr. Tampi is the Past President of the American Association for Geriatric Psychiatry (AAGP). He was the President of the AAGP for 2019-2020 and the Co-President for 2020-2021. Dr. Tampi was the Secretary and Treasurer of the AAGP for 2017-2018. He was the Program Chair for the 2017 AAGP Annual Meeting, Dallas, Texas. Dr. Tampi is the Past President of the International Medical Graduates (IMG) Caucus at the American Psychiatric Association (APA). He is a Distinguished Fellow of the APA and of the AAGP.

Dr. Tampi is a graduate of the University of Kerala, Kerala, India. He trained in Psychiatry at the University of Leeds, Leeds, England and at the University of Vermont, Burlington, Vermont. During his residency training in England, Dr. Tampi also attained a Post Graduate Diploma in Clinical Psychiatry from the University of Leeds. He completed his Geriatric Psychiatry Fellowship at Yale School of Medicine.  Dr. Tampi has received three ‘Outstanding Teaching Attending Awards’ and the ‘Chairman’s Award’ for outstanding teaching, research and clinical work from the Department of Psychiatry at Yale School of Medicine. He received the ‘Teacher of the Year’ Award from the Department of Psychiatry, Case Western Reserve University MetroHealth Program in 2015, 2016 and 2018.  Dr. Tampi is a recipient of the Geriatric Academic Career Award (GACA) instituted by the Department of Health and Human Services (DHHS). He was a recipient of the AAGP’s ‘Clinician of the Year Award’ in 2013.  Dr. Tampi also received the AAGP’s ‘Recognition and Appreciation’ Certificate in 2018. In 2019, he received the AAGP’s ‘Educator of the Year Award’. Dr. Tampi received the ‘2019 Outstanding Academician of the Year Award’ given by the Indo-American Psychiatric Association (IAPA). He is the recipient of the 2021 Jack Weinberg Award for Geriatric Psychiatry given by the APA.  Dr. Tampi has over 180 publications on various topics in psychiatry and geriatric psychiatry. In addition, he is the Editor of 9 books in psychiatry published by reputed publishers including Lippincott Williams & Wilkins (LWW), Oxford University Press (OUP), Springer International Publishing (SIP) and Cambridge University Press (CUP).

Dr. Tampi serves as the Editor-in-Chief of the World Journal of Psychiatry, Associate Editor for Drugs in Context (Psychiatry), Associate Editor for Aging Psychiatry Section of Frontiers in Psychiatry and the Section Editor of Geriatric Psychiatry for Psychiatric Times. He is on the Editorial Board of ‘Clinical Interventions in Aging’, the ‘Annals of Clinical Psychiatry’ and ‘Therapeutic Advances in Psychopharmacology’. Furthermore, Dr. Tampi serves as an ad-hoc peer reviewer for 52 journals including the American Journal of Geriatric Psychiatry, the American Journal of Psychiatry, JAMA Psychiatry, the Journal of American Geriatrics Society and the American Journal of Alzheimer’s Disease and other Dementias amongst others.  Dr. Tampi’s clinical and research interests are the management of psychiatric disorders in late life, neurodegenerative disorders, ethical & legal issues in geriatric psychiatry, integrated geriatric -psychiatric care and undergraduate and postgraduate education in psychiatry and geriatric psychiatry.


Disclosure: Dr. Tampi has no relevant financial relationship(s), potential or perceived, with commercial or conflicts of interest to disclose. 
 
 

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2023

CE Hours

1.00
   

   

 
Treatment of Agitation and Impulsivity in Autism
 
 
Facutly Information TBA
 
 
LEARNING OBJECTIVES
  • TBA
ABOUT THE FACULTY
  • TBA
 
 

Release Date: Oct 22, 2021
Credit Expiration Date: Oct 20, 2023

CE Hours

1.00
   

   

 
Acute Pain Management with Patients with OUD
 
 
Kirsten Mason, PharmD, BCPS
Regional Clinical Pharmacy Manager
Ascension Texas
 
 
LEARNING OBJECTIVES
  • Develop an approach to manage pain with hospitalized individuals with opioid use disorder (OUD)
  • Compare pain management strategies for individuals with OUD taking buprenorphine, methadone, extended release naltrexone, and non-prescribed opioids
  • Review transitions of care considerations for patients with OUD
ABOUT THE FACULTY

Dr. Kirsten Mason is a graduate of the University of Tennessee Health Science Center College of Pharmacy. She completed her PGY1 Pharmacy Residency at Memphis Veterans Affairs Medical Center and her PGY2 Internal Medicine Residency at University Medical Center Brackenridge in Austin, TX. Immediately after residency training, Dr. Mason accepted a clinical pharmacy specialist position in cardiology at Northwestern Memorial Hospital in Chicago. In 2016, she had an opportunity to relocate back to Austin and she joined Dell Seton Medical Center at University of Texas as an Internal Medicine Clinical Pharmacy Specialist. In this role, she assisted in the development of an inpatient opioid use disorder treatment service. In November of 2018, Dr. Mason transitioned roles within Ascension Texas to a Regional Clinical Pharmacy Manager with an emphasis on project management and pain management. She also serves as a preceptor for University of Texas College of Pharmacy and Texas A&M College of Pharmacy. Dr. Mason continues to advocate for treatment of opioid use disorder across the continuum of care and educate healthcare providers about medications for opioid use disorder. More recently, Dr. Mason is serving as Interim Director of Pharmacy at Ascension Seton Northwest.


Disclosure: Dr. Mason has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Consultant: Macromoltek Grant Consultant

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

 This project is funded by Texas Health & Human Services Texas Targeted Opioid Response.
 

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2023

CE Hours

1.00
   

   

 
Role of Stigma in Opioid Use Disorder
 
 
Richard Bottner, PA-C
Assistant Professor, Department of Internal Medicine
The University of Texas at Austin Dell Medical School
 
 
LEARNING OBJECTIVES
  • Define stigma and its historical origins
  • Identify different types of stigma
  • Discuss how stigma decreased access to care for people with substance use disorders
 
ABOUT THE FACULTY

Richard Bottner, DHA, PA-C is an Assistant Professor in the Department of Internal Medicine at Dell Medical School at The University of Texas at Austin. Bottner is also a physician assistant in the Division of Hospital medicine at Dell Seton Medical Center. Bottner is the Director of the Buprenorphine Team (B-Team), a full-service consultation team that provides patients who are hospitalized and have opioid use disorder access to treatment and linkage to appropriate outpatient care. The program also works to reduce stigma of patients with substance use disorders. Bottner is also the Director of Support Hospital Opioid Use Treatment (SHOUT) Texas, a TTOR-funded program seeking to increase access to opioid use disorder treatment in hospitals across the state.


Disclosure: Richard Bottner has no relevant financial relationship(s) with commercial interests or conflicts of interest to disclose.

 This project is funded by Texas Health & Human Services Texas Targeted Opioid Response.
 

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2023

CE Hours

1.00
   

   

 
New Agents for Mental Health and Neurologic Disorders
 
 
Stephen R. Saklad, Phrm.D., BCPP
Clinical Professor of Pharmacotherapy
Director, Psychiatric Pharmacy Program
Adjoint Professor, School of Medicine
Clinical Pharmacologist, San Antonio State Hospital, Texas Department of State Health Services
 
 
 
LEARNING OBJECTIVES
  • Describe the efficacy and safety data of the emerging and recently approved psychiatric and neurologic medication pipeline.
  • Discuss appropriate monitoring requirements, patient education points, and provider education for these agents.
  • Discuss clinical use of new and emerging medications
ABOUT THE FACULTY

Dr. Saklad was born in Los Angeles, California in 1953, and graduated from Pacific Palisades High School in 1970. He received his baccalaureate degree cum laude in Bacteriology from the University of California, Los Angeles in 1974. His Doctor of Pharmacy degree was earned at the University of Southern California in 1978. He had a National Institute of Mental Health training fellowship in Psychiatric Pharmacy supervised by Jim Wilson, Pharm.D., BCPP at the Nebraska Psychiatric Institute of the University of Nebraska Medical Center at Omaha in 1978-9. He then joined the faculty of The University of Texas at Austin College of Pharmacy and the clinical staff at San Antonio State Hospital (SASH) in 1979. He was the first clinical pharmacist employed by the Texas Department of Mental Health and Mental Retardation (now Texas Health and Human Services) when he began as Clinical Coordinator at SASH. He has lived in San Antonio, Texas since 1979. He is married and the father of triplet sons.

During his 38 years career, Dr. Saklad has provided clinical care, education, and research in a variety of settings and treatment roles at SASH. He team teaches didactic courses for second and third professional year pharmacy students. He is the course director for Advanced Pharmacotherapy Laboratory, a third professional year opportunity for students to develop their clinical presentation skills that is given across four campuses. He precepts and mentors third and fourth professional year pharmacy students (P3’s & P4’s) at SASH. He received the UT Austin College of Pharmacy’s Teaching Award from the Class of 2014. He authored and successfully discussed with members of the Texas Legislature the creation of a clinical research unit at SASH that was funded by the Texas Legislature and jointly governed by the UT Austin College of Pharmacy, UT Health Science Center San Antonio Department of Psychiatry and SASH.

Dr. Saklad initiated and developed the first websites for the UT Austin College of Pharmacy in 1994, the College of Psychiatric and Neurologic Pharmacists (CPNP) in 1997, and the CPNP Foundation in 2015. He helped to design, organize and was a founding member of CPNP when it incorporated in 1998 as well as the CPNP Foundation in 2012. In 2003, he was elected to the Board of Directors of the CPNP for a two-year term. He has served as a member or officer of the CPNP Communications Committee since the creation of CPNP from 1995 to 2011 and was the Founding Senior Editor of the Mental Health Clinician, CPNP’s Open Access journal, from 2011-13. Currently, Dr. Saklad is Treasurer of the CPNP Foundation a member of the CPNP Business Development Committee. He was on the task force that developed The Mental Health Pharmacy Directory to improve patient access. He is the Director of The University of Texas Psychiatric Pharmacy Program. In 1988, he helped to create and has chaired The University of Texas at Austin College of Pharmacy’s Psychiatric Pharmacotherapy Update since 2007.

Dr. Saklad publishes articles and presents to many groups around the country on a variety of pharmacy and mental health-related topics. He edited Psychopharmacology Update newsletter from 1998-2002 and edited two editions of a compendium based upon this newsletter, Psychopharmacology Desktop Reference, published by Manisses Communications Group in 1999 and 2002. He provides updates on his Twitter feed on a variety of topics @pharmacopsych.

Dr. Saklad is a principal or co-investigator for several studies of the efficacy and adverse effects of Phase II, III, and IV psychotropic agents in schizophrenia, mood disorders, depression, and other serious and persistent mental illness, as well as their pharmacokinetics and interactions. He was the Director of UT Health Science Center San Antonio’s Advanced Pharmacotherapy Research with research facilities located at Laurel Ridge Treatment Center and President of Alamo Superior Research, LLC. He has been affiliated with the Behavioral Wellness (“Be Well”) Center, Department of Psychiatry, UT Health San Antonio since 2009.


Disclosure: Dr. Saklad has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:

Employee of Texas Department of Health Services San Antonio
Speakers Bureau: Actavis, Otsuka, Sunovion
Consultant: Janssen, Jazz, Otsuka, Teva
Other: Member of Pharmacists Foundation, Business Development Council for San Antonio

Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.

 
 

Release Date: Oct 21, 2021
Credit Expiration Date: Jun 18, 2023

CE Hours

1.00
   

   

 
Tardive Dyskinesia Update
 
 
Steve Stoner, PharmD, BCPP
Chair and Clinical Professor
Division of Pharmacy Practice and Administration
University of Missouri - Kansas City School of Pharmacy
 
 
 
LEARNING OBJECTIVES
  • Review 2020 American Psychiatric Association Guidelines for the treatment of patients with schizophrenia who develop tardive dyskinesia.
  • Critique short and long-term treatment considerations for managing tardive dyskinesia and discuss the role of VMAT2 inhibitors in the treatment continuum of tardive dyskinesia
  • Explore the detrimental impact of tardive dyskinesia on global functionality and demonstrate how VMAT2 inhibitors can improve functionality and overall quality of life (e.g., improved mobility, self- care, social activities, and life responsibilities).
ABOUT THE FACULTY
Dr. Steve Stoner is a 1994 graduate of the University of Nebraska College of Pharmacy who also completed a Psychiatric Pharmacy Residency and Fellowship at Western Missouri Mental Health Center (1994-1996). In 1996, Dr. Stoner joined the UMKC School of Pharmacy as a Clinical Assistant Professor and established a clinical practice at the Northwest Missouri Psychiatric Rehabilitation Center where he also started a Psychiatric Pharmacy Residency Program. In 2002, Dr. Stoner was promoted to Clinical Associate Professor and in 2007 was promoted to Clinical Professor. In 2008, he assumed the role of Interim Department Chair of Pharmacy Practice and became the permanent chair in 2008, a position he held until 2020. In 2020, Dr. Stoner was named the Associate Dean for Student Affairs. Dr. Stoner has held several leadership positions within local, regional, and national pharmacy organizations. Notably, Dr. Stoner is a Past-President of the College of Psychiatric and Neurologic Pharmacists Association and within the American Association of Colleges of Pharmacy he has served as the Chair of the Pharmacy Practice Section and Chair of the Council of Sections. Dr. Stoner’s scholarly endeavors have included research efforts in the disease state areas of schizophrenia, depression, drug-induced movements, and bipolar disorder. In addition, he has published in pharmacy education on topics related to course design, student learning outcomes, and student wellness as it relates to the use of smartphone devices. Dr. Stoner has also received several teaching and preceptor awards during his time at UMKC.
 

Disclosure: Dr. Stoner has the following relevant financial relationships, potential or perceived, with commercial or conflicts of interest to disclose:
• Research Grant Support: Alkermes Pharmaceuticals
• Consultant: Neurocrine Pharmaceuticals
• Speaker’s Bureau: Neurocrine Pharmaceuticals
• Honorarium: TEVA Pharmaceuticals
 
Review of Conflicts Policy: The UT Austin College of Pharmacy has a very strict policy to ensure against commercial conflicts of interest in CE programming. For this conference, the planning committee picks two committee members who have appropriate backgrounds to review content, and report any potential conflict of interest to the CPE Director. If conflict issues are discovered, they are addressed with speakers to make appropriate changes. Evaluations are collected from all participants with specific questions around the listed conflicts of commercial interest.
 
 
 

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2023

CE Hours

1.00
   

   

 
Overcoming Barriers to Clozapine
 
 
Deanna L. Kelly, PharmD., BCPP
Professor of Psychiatry Director, Treatment Research Program (TRP)
Maryland Psychiatric Research Center (MPRC)
University of Maryland School of Medicine
 
 
LEARNING OBJECTIVES
  • Discuss the utility of clozapine in the treatment resistant schizophrenia
  • List significant barriers to the use of clozapine
  • Recognize new data and strategies to overcome some barriers to clozapine use including point of care monitoring, new plasma level assay, and emerging data in patients with Benign Ethnic Neutropenia
ABOUT THE FACULTY
  • TBA
 
 

CE Hours

1.00
   

   

 
On-Demand Session TBA
 
 
Facutly Information TBA
 
 
LEARNING OBJECTIVES
  • TBA
ABOUT THE FACULTY
  • TBA
 
 

Release Date: Oct 21, 2021
Credit Expiration Date: Oct 20, 2023

CE Hours

1.00
   

   

 
Become an Online Exhbitor for the Psychiatric Pharmacotherapy Update!
 
 
Place your content and information here
  • Contact Glen Baumgart - Director of Continuing Education at The University of Texas at Austin College of Pharmacy at gbaumgart@austin.utexas.edu
 
 

   

   

 
Become an Online Exhbitor for the Psychiatric Pharmacotherapy Update!
 
 
Place your content and information here
  • Contact Glen Baumgart - Director of Continuing Education at The University of Texas at Austin College of Pharmacy at gbaumgart@austin.utexas.edu
 
 

   

   

 
Become an Online Exhbitor for the Psychiatric Pharmacotherapy Update!
 
 
Place your content and information here
  • Contact Glen Baumgart - Director of Continuing Education at The University of Texas at Austin College of Pharmacy at gbaumgart@austin.utexas.edu
 
 

   

   

 
Become an Online Exhbitor for the Psychiatric Pharmacotherapy Update!
 
 
Place your content and information here
  • Contact Glen Baumgart - Director of Continuing Education at The University of Texas at Austin College of Pharmacy at gbaumgart@austin.utexas.edu
 
 

   

   

 
Become an Online Exhbitor for the Psychiatric Pharmacotherapy Update!
 
 
Place your content and information here
  • Contact Glen Baumgart - Director of Continuing Education at The University of Texas at Austin College of Pharmacy at gbaumgart@austin.utexas.edu
 
 

   

   

 
Become an Online Exhbitor for the Psychiatric Pharmacotherapy Update!
 
 
Place your content and information here
  • Contact Glen Baumgart - Director of Continuing Education at The University of Texas at Austin College of Pharmacy at gbaumgart@austin.utexas.edu
 
 

   

   

 
Become an Online Exhbitor for the Psychiatric Pharmacotherapy Update!
 
 
Place your content and information here
  • Contact Glen Baumgart - Director of Continuing Education at The University of Texas at Austin College of Pharmacy at gbaumgart@austin.utexas.edu
 
 

   

   

 
Become an Online Exhbitor for the Psychiatric Pharmacotherapy Update!
 
 
Place your content and information here
  • Contact Glen Baumgart - Director of Continuing Education at The University of Texas at Austin College of Pharmacy at gbaumgart@austin.utexas.edu